Tolerability of cefazolin after immune-mediated hypersensitivity reactions to nafcillin in the outpatient setting

Kimberly G. Blumenthal*, Ilan Youngster, Erica S. Shenoy, Aleena Banerji, Sandra B. Nelson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

The objective of the present study was to assess the safety and tolerability of cefazolin therapy among patients with methicillinsensitive Gram-positive bacterial infections who develop non-IgE-mediated hypersensitivity reactions (HSRs) to nafcillin. In this retrospective cohort analysis of the Outpatient Parenteral Antimicrobial Therapy program at the Massachusetts General Hospital from 2007 through 2013, we identified patients switched from nafcillin to cefazolin after an immune-mediated HSR. We reviewed patient demographics, details about the original HSR, and outcomes after the switch to cefazolin therapy. HSRs were classified by reaction type and likely mechanism. There were 467 patients treated with nafcillin, of which 60 (12.8%) were switched to cefazolin during their prescribed course. Of the 60 patients who transitioned to cefazolin, 17 (28.3%) were switched because of non-IgE-mediated HSRs. HSRs included maculopapular rash (n=10), immune-mediated nephritis (n=3), isolated eosinophilia (n=2), immune-mediated hepatitis (n=1), and a serum sickness-like reaction (n=1). All but one patient (94.1%) who switched to cefazolin tolerated the drug with resolution of the HSR and completed their therapy with cefazolin. No patient experienced worsening of their rash or progressive organ dysfunction. With appropriate monitoring, therapy with cefazolin after non-IgE-mediated HSRs to nafcillin appears to be safe.

Original languageEnglish
Pages (from-to)3137-3143
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number6
DOIs
StatePublished - Jun 2014
Externally publishedYes

Funding

FundersFunder number
National Institutes of Health
National Institute of Allergy and Infectious DiseasesK01AI110524

    Fingerprint

    Dive into the research topics of 'Tolerability of cefazolin after immune-mediated hypersensitivity reactions to nafcillin in the outpatient setting'. Together they form a unique fingerprint.

    Cite this